Compare Abeona Therapeutics Inc (ABEO) vs AMETEK, Inc. (AME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs AMETEK, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $424.33M), while AMETEK, Inc. trades at $255.78 (market cap $57.98B). The key difference: AMETEK, Inc. is far larger — about 136.6× Abeona Therapeutics Inc's market cap, and AMETEK, Inc. pays a 0.54% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AME | |
|---|---|---|
Market Cap | $424.33M | $57.98B |
Sector | Health | Industrials |
52-Week High | $7.45 | $254.76 |
52-Week Low | $4.17 | $179.28 |
Enterprise Value | $279.23M | $59.52B |
Dividend Yield | — | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
AME trades at $253.66, up 0.91% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $2.09 vs. $1.99 expected), revenue growth to $7.40B in 2025, and robust profitability (20.04% net margin). Recent news highlights momentum in 3D printing and electronics testing sectors. Analyst consensus is strongly bullish with a $281.86 price target.
Outlook remains positive given earnings momentum and raised guidance, but risks include elevated valuation (P/E 37.08) and RSI overbought signals. Institutional support is strong with no sell ratings. The stock offers growth potential but requires monitoring of valuation metrics amid current levels near resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →
